OTTAWA, Dec. 23, 2020 (GLOBE NEWSWIRE) - OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, today announced that its OMNIgene®·ORAL (OM/OME-505) collection device was included in the U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) amendment granted to 3B BlackBio Biotech, one of the leading suppliers and developers for RT-PCR diagnostic assays in India. This is the seventh customer EUA that includes a collection device from the company’s DNA Genotek subsidiary.Read more
- Home
-
Products
-
-
Oncology
- Panel Kits
-
Individual Markers
- C-KIT Mutation Detection
- CALR Mutations Detection
- CXCR4 Mutations Detection
- DPYD Mutations Detection
- FLT3 Mutation Detection
- JAK2 QL Mutations Detection
- JAK2 Quantitative (Allele Burden)
- MYD88 Mutations Detection
- NPM1 Mutation Quantitative
- NPM1 Mutations Qualitative
- PML-RARA Qualitative
- PML-RARA Quantitative
- Individual Markers BCR-ABL1
- Solid Tumor-Individual Markers
- Human Genetics
-
Infectious Diseases
- Panel Kits
-
Individual Pathogens – Viruses
- BKV Viral Load
- Chikungunya Detection
- CMV Viral Load
- Dengue Detection
- Dengue/Chikungunya Detection
- EBV Viral Load
- H1N1 Detection
- HBV Viral Load
- HCV Detection and Genotyping
- HCV Viral Load
- HIV 1/2 Detection
- HIV Viral Load
- HPV 16 & 18 Detection
- HPV High Risk Genotyping
- HSV1/2 Detection
- SARS-CoV-2 Detection
- SARS-CoV-2 Detection (CE)
- ZIKA Detection
- Individual Pathogens – Bacteria
- Individual Pathogens – Parasites
- Antimicrobial Resistance
- Extraction Kits
- Rapid Diagnostics - TRURAPID®
-
Oncology
-
- Careers
- Support
